We have a scalable alliance model that seeks to balance our participation in downstream value with near-term cash, while minimizing use of Xencor resources and staff. Our goal is to create a broad pipeline of partnered candidates that use Xencor technology while focusing internal efforts on, and retaining rights for, our proprietary drug candidates.
For our XmAb® Fc technology, our strategy has been to license the same set of high-performance Fc domains to multiple partners for use only with specific targets. Because any given XmAb® Fc works to improve function in nearly any antibody, XmAb®alliances require only the transfer of information regarding pre-existing optimized XmAb® Fcs and do not require any significant internal resources. We also seek to partner our XmAb®variable region humanization and affinity optimization tools allowing collaborators to access complete antibody candidate generation capabilities from Xencor.
We also partner the use of our XPro® tools to optimize the performance of therapeutic proteins, and license elements of our PDA® platform, in particular our ImmunoFilter™ safety screening database, for use by partners.
In the future, we will continue to selectively partner our proprietary therapeutic candidates to enable late-stage clinical development or to increase the number of programs that can commence clinical development.